{
   "search": [
       {
           "page": "Press Release",
           "title": "Gilead and GlaxoSmithKline Announce International Licensing Agreement for Investigational Chronic Hepatitis B Drug Adefovir Dipivoxil",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ..."
       },
       {
          "page": "Press Release",
           "title": "Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronical Hepatitis B Virus Meets Primary Endpoint",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Medicines",
           "title": "Chronic Hepatitis B Fact Sheet",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
          "page": "Giving & Access",
           "title": "Corporate Grants and Giving",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Press Release",
           "title": "Gilead and GlaxoSmithKline Announce International Licensing Agreement for Investigational Chronic Hepatitis B Drug Adefovir Dipivoxil",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ..."
           
       },
       {
          "page": "Press Release",
           "title": "Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronical Hepatitis B Virus Meets Primary Endpoint",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Medicines",
           "title": "Chronic Hepatitis B Fact Sheet",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
          "page": "Giving & Access",
           "title": "Corporate Grants and Giving",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Press Release",
           "title": "Gilead and GlaxoSmithKline Announce International Licensing Agreement for Investigational Chronic Hepatitis B Drug Adefovir Dipivoxil",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ..."
       },
       {
          "page": "Press Release",
           "title": "Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronical Hepatitis B Virus Meets Primary Endpoint",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Medicines",
           "title": "Chronic Hepatitis B Fact Sheet",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
          "page": "Giving & Access",
           "title": "Corporate Grants and Giving",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Press Release",
           "title": "Gilead and GlaxoSmithKline Announce International Licensing Agreement for Investigational Chronic Hepatitis B Drug Adefovir Dipivoxil",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ..."   
       },
       {
          "page": "Press Release",
           "title": "Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronical Hepatitis B Virus Meets Primary Endpoint",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Medicines",
           "title": "Chronic Hepatitis B Fact Sheet",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
          "page": "Giving & Access",
           "title": "Corporate Grants and Giving",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Press Release",
           "title": "Gilead and GlaxoSmithKline Announce International Licensing Agreement for Investigational Chronic Hepatitis B Drug Adefovir Dipivoxil",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ..."
       },
       {
          "page": "Press Release",
           "title": "Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronical Hepatitis B Virus Meets Primary Endpoint",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Medicines",
           "title": "Chronic Hepatitis B Fact Sheet",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
          "page": "Giving & Access",
           "title": "Corporate Grants and Giving",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Press Release",
           "title": "Gilead and GlaxoSmithKline Announce International Licensing Agreement for Investigational Chronic Hepatitis B Drug Adefovir Dipivoxil",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ..."
       },
       {
          "page": "Press Release",
           "title": "Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronical Hepatitis B Virus Meets Primary Endpoint",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Medicines",
           "title": "Chronic Hepatitis B Fact Sheet",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
          "page": "Giving & Access",
           "title": "Corporate Grants and Giving",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Press Release",
           "title": "Gilead and GlaxoSmithKline Announce International Licensing Agreement for Investigational Chronic Hepatitis B Drug Adefovir Dipivoxil",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ..."
       },
       {
          "page": "Press Release",
           "title": "Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronical Hepatitis B Virus Meets Primary Endpoint",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Medicines",
           "title": "Chronic Hepatitis B Fact Sheet",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
          "page": "Giving & Access",
           "title": "Corporate Grants and Giving",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Press Release",
           "title": "Gilead and GlaxoSmithKline Announce International Licensing Agreement for Investigational Chronic Hepatitis B Drug Adefovir Dipivoxil",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ..."
       },
       {
          "page": "Press Release",
           "title": "Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronical Hepatitis B Virus Meets Primary Endpoint",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Medicines",
           "title": "Chronic Hepatitis B Fact Sheet",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
          "page": "Giving & Access",
           "title": "Corporate Grants and Giving",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Press Release",
           "title": "Gilead and GlaxoSmithKline Announce International Licensing Agreement for Investigational Chronic Hepatitis B Drug Adefovir Dipivoxil",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ..."
           
       },
       {
          "page": "Press Release",
           "title": "Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronical Hepatitis B Virus Meets Primary Endpoint",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Medicines",
           "title": "Chronic Hepatitis B Fact Sheet",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
          "page": "Giving & Access",
           "title": "Corporate Grants and Giving",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Press Release",
           "title": "Gilead and GlaxoSmithKline Announce International Licensing Agreement for Investigational Chronic Hepatitis B Drug Adefovir Dipivoxil",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ..."
       },
       {
          "page": "Press Release",
           "title": "Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronical Hepatitis B Virus Meets Primary Endpoint",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Medicines",
           "title": "Chronic Hepatitis B Fact Sheet",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
          "page": "Giving & Access",
           "title": "Corporate Grants and Giving",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Press Release",
           "title": "Gilead and GlaxoSmithKline Announce International Licensing Agreement for Investigational Chronic Hepatitis B Drug Adefovir Dipivoxil",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ..."   
       },
       {
          "page": "Press Release",
           "title": "Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronical Hepatitis B Virus Meets Primary Endpoint",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Medicines",
           "title": "Chronic Hepatitis B Fact Sheet",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
          "page": "Giving & Access",
           "title": "Corporate Grants and Giving",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Press Release",
           "title": "Gilead and GlaxoSmithKline Announce International Licensing Agreement for Investigational Chronic Hepatitis B Drug Adefovir Dipivoxil",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ..."
       },
       {
          "page": "Press Release",
           "title": "Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronical Hepatitis B Virus Meets Primary Endpoint",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Medicines",
           "title": "Chronic Hepatitis B Fact Sheet",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
          "page": "Giving & Access",
           "title": "Corporate Grants and Giving",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Press Release",
           "title": "Gilead and GlaxoSmithKline Announce International Licensing Agreement for Investigational Chronic Hepatitis B Drug Adefovir Dipivoxil",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ..."
       },
       {
          "page": "Press Release",
           "title": "Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronical Hepatitis B Virus Meets Primary Endpoint",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Medicines",
           "title": "Chronic Hepatitis B Fact Sheet",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
          "page": "Giving & Access",
           "title": "Corporate Grants and Giving",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Press Release",
           "title": "Gilead and GlaxoSmithKline Announce International Licensing Agreement for Investigational Chronic Hepatitis B Drug Adefovir Dipivoxil",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ..."
       },
       {
          "page": "Press Release",
           "title": "Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronical Hepatitis B Virus Meets Primary Endpoint",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Medicines",
           "title": "Chronic Hepatitis B Fact Sheet",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
          "page": "Giving & Access",
           "title": "Corporate Grants and Giving",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Press Release",
           "title": "Gilead and GlaxoSmithKline Announce International Licensing Agreement for Investigational Chronic Hepatitis B Drug Adefovir Dipivoxil",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ..."
       },
       {
          "page": "Press Release",
           "title": "Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronical Hepatitis B Virus Meets Primary Endpoint",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Medicines",
           "title": "Chronic Hepatitis B Fact Sheet",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
          "page": "Giving & Access",
           "title": "Corporate Grants and Giving",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Press Release",
           "title": "Gilead and GlaxoSmithKline Announce International Licensing Agreement for Investigational Chronic Hepatitis B Drug Adefovir Dipivoxil",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ..."
           
       },
       {
          "page": "Press Release",
           "title": "Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronical Hepatitis B Virus Meets Primary Endpoint",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Medicines",
           "title": "Chronic Hepatitis B Fact Sheet",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
          "page": "Giving & Access",
           "title": "Corporate Grants and Giving",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Press Release",
           "title": "Gilead and GlaxoSmithKline Announce International Licensing Agreement for Investigational Chronic Hepatitis B Drug Adefovir Dipivoxil",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ..."
       },
       {
          "page": "Press Release",
           "title": "Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronical Hepatitis B Virus Meets Primary Endpoint",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Medicines",
           "title": "Chronic Hepatitis B Fact Sheet",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
          "page": "Giving & Access",
           "title": "Corporate Grants and Giving",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Press Release",
           "title": "Gilead and GlaxoSmithKline Announce International Licensing Agreement for Investigational Chronic Hepatitis B Drug Adefovir Dipivoxil",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ..."   
       },
       {
          "page": "Press Release",
           "title": "Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronical Hepatitis B Virus Meets Primary Endpoint",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Medicines",
           "title": "Chronic Hepatitis B Fact Sheet",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
          "page": "Giving & Access",
           "title": "Corporate Grants and Giving",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Press Release",
           "title": "Gilead and GlaxoSmithKline Announce International Licensing Agreement for Investigational Chronic Hepatitis B Drug Adefovir Dipivoxil",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ..."
       },
       {
          "page": "Press Release",
           "title": "Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronical Hepatitis B Virus Meets Primary Endpoint",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Medicines",
           "title": "Chronic Hepatitis B Fact Sheet",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
          "page": "Giving & Access",
           "title": "Corporate Grants and Giving",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Press Release",
           "title": "Gilead and GlaxoSmithKline Announce International Licensing Agreement for Investigational Chronic Hepatitis B Drug Adefovir Dipivoxil",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ..."
       },
       {
          "page": "Press Release",
           "title": "Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronical Hepatitis B Virus Meets Primary Endpoint",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Medicines",
           "title": "Chronic Hepatitis B Fact Sheet",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
          "page": "Giving & Access",
           "title": "Corporate Grants and Giving",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Press Release",
           "title": "Gilead and GlaxoSmithKline Announce International Licensing Agreement for Investigational Chronic Hepatitis B Drug Adefovir Dipivoxil",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ..."
       },
       {
          "page": "Press Release",
           "title": "Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronical Hepatitis B Virus Meets Primary Endpoint",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
           "page": "Medicines",
           "title": "Chronic Hepatitis B Fact Sheet",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       },
       {
          "page": "Giving & Access",
           "title": "Corporate Grants and Giving",
           "description": "More than half a billion people worldwide are infected with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), both of which ... "
       }
   ]
}



